3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (May 2019)
41 slides from 3b Blackbio Dx's investor presentation, May 23, 2019
Slide 1: Kilpest India Limited cover letter to BSE
~,"~",,~~l ISO 900.., = 2000 KILPEST REGD. OFFICE & FACTORY: Tel FAX NO. Email INDIA LIMITED 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 (INDIA) (91-755) 2586536, 2586537, 2586439 (91-755) 2580438 kilpest@bsnl.in visit us at: www.kilpest.com kilpestbpl@yahoo.co.in GIN: L24211MP1972PLC001131 M
Slide 2: Investor Presentation FY 2019
Farmers trusted Agro-input partner for 46 years Reliable & affordable healthcare diagnostics solutions INVESTOR PRESENTATION FY 2019
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the ―Presentation‖), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the ―Company‖), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides - 70 • Bio pesticide - 07 • Antibacterials - 01 • Bio fungicide - 01 • Fungicides - 15 • Bio fertilizers - 05 • Herbicides - 11 • Bio nematicides - 01 • Public Health - 11 • Public Health - 02 • Microferti
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of art facility located in center of India- with GST implementation this should give a boost to the company • 46yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially in Madhya
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights KILPEST (Consolidated) FY19 FY18 0.28% 695.14 53.93% 2327.67 Net sales (FY18 net of Excise Duty) 2327.67 2321.26 FY19 451.59 Profit before tax 695.14 451.59 FY18 2321.26 Profit after tax 524.17 342.60 Paid up Equity share capital 640.81 640.81 Revenue PBT (CONS
Slide 7: Financial Performance: Key Highlights
Financial Performance : Key Highlights KILPEST (Consolidated) Q4 FY19 Q4 FY18 611.67 11.03% 97.09% 198 Net sales (FY18 net of Excise Duty) 611.67 550.90 FY19 198.00 100.46 Profit before tax FY18 100.46 550.9 Profit after tax 124.02 58.38 Paid up Equity share capital 640.81 640.81 Revenue PBT (CONSOL
Slide 8: Present Market Overview/Outlook
Present Market Overview/Outlook • This year monsoon has been below normal, affecting sales of company. • This year has been bad in history of Agrochemicals, in terms of shortage and increase in raw material prices, which affected company’s profitability. • The company’s agrochemical sales has come t
Slide 9: From the house of KILPEST INDIA LTD.
Since 1972 From the house of KILPEST India Ltd., India‘s most trusted agro-chemical KILPEST INDIA brand proudly brings LTD. First licensed IVD manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 10: 3B BlackBio Biotech India Limited
From the house of KILPEST India Ltd. 3B BlackBio Biotech India Limited; has become India‘s leading healthcare company specialized in the development of molecular biology fine-chemicals as tools for diagnostic/pathology segment of healthcare. The Company is CDSCO Licensed, ISO 13485:2016 certified, G
Slide 11: TRUPCR Vision and Mission
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Vision Reliable and affordable healthcare solutions for all Mission 3B BlackBio Biotech (I) Ltd. with its TRUPCR® brand of products is committed to design and develop molecular diagnostics products of superior quality and value that continuously improves the
Slide 12: Timeline & Milestones
Timeline & Milestones Launching Oncopanels Launch of Extending Solid Tumor AML Menu with ALL Virology & EGFR MPN Public Health KRAS Adding Acquisition of Virology HBV, HCV NGS & Expanding HCV Genotyping Entering Menu HIV1/2 Oncology & Human Dengue, H1N1 First product HBV Chikungunya Genetics Incepti
Slide 13: Growth Canvas
Growth Canvas Sales (Rs. In Lakhs) Customers ₹1,200.00 160 ₹1,118.93 140 ₹1,000.00 120 ₹800.00 ₹765.05 100 ₹600.00 80 60 ₹400.00 ₹315.89 40 ₹200.00 ₹164.56 ₹94.56 ₹100.73 20 ₹0.00 0 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 Sales (Rs. In Lakhs) ₹94.56 ₹100.73 ₹164.56 ₹315.89 ₹765.05 ₹1,118.93
Slide 14: Financial Highlights FY'19
Financial Highlights FY‘19 1118.93 46.26% 676.81 56.26% 765.04 433.13 Revenue EBITDA 650.99 64.93% 65.58% 481.19 394.7 290.6 FY'19 FY'18 PBT Rs. In Lakhs. PAT ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 15: Financial Highlights Q4-FY'19
Financial Highlights Q4-FY‘19 354.45 74.35% 81.48% 202.28 203.29 111.46 Revenue EBITDA 197.59 92.11% 119.86 120.49% 102.85 54.36 Q4 FY'19 Q$ FY'18 PBT Rs. In Lakhs. PAT ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 16: Our Beneficiaries
Our Beneficiaries FOR PATIENTS FOR LABORATORIES CLINICALLY VALIDATED PRECISE TRUPCR® kits are calibrated to WHO standards and clinically validated TRUPCR® offers highly sensitive and precise qPCR assays as on wide variety and numbers of samples. indicated by minimum variability of replicates and mul
Slide 17: Our Team
Our Team • A team of highly motivated individuals who seek to bring a positive change in the lives of people through their hard work and dedication. • We are a group of molecular biologists working towards a common goal of developing reliable molecular tools which can help healthcare practitioners t
Slide 18: Work Process
Work Process PLAN RESEARCH Feasibility DESIGN DEVELOP VALIDATIONS APPROVALS COMMERCIALIZATION (Technical & Commercial) IMPROVEMENT SUPPORT ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 19: R&D
R&D People • Highly educated team of scientist from varied backgrounds • Dedicated teams for respective segments • Separate onco team headed by researchers (Ph.Ds.) from oncology background • Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background L
Slide 20: Product QC – Our Strength
Product QC – Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 21: Our Certificates
Our Certificates ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 22: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B‘s Focus Low Growth High Growth Other Molecular Techniques Sanger Sequencing Next Generation Mass Spec Sequencing Hybridization Microarray Low Volume ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 23: Molecular Diagnostics
Molecular Diagnostics • The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. • Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual‘s genetic code and how their cells express the
Slide 24: Molecular diagnostics market size source
Source-https://www.gminsights.com/pressrelease/molecular-diagnostics-market-size
Slide 25: Product Segments
Product Segments Molecular Microbiology Molecular Oncology Human Genetics SYNDROMES & INFECTIONS CANCERS DISORDERS Individual Markers Individual Markers Individual Markers Infectious Panels Oncology Panels Genetic Panels ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALT
Slide 26: Product Range
Product Range ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 27: Product Range
Product Range ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 28: All-Inclusive TRUPCR products
All-Inclusive TRUPCR® products TRUPCR range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis TRUPCR Nucleic Acid Extraction ki
Slide 29: Next Generation Sequencing Assays
Next Generation Sequencing Launching soon… Next Generation Sequencing Assays Real image of NGS facility at 3B BlackBio Biotech (I) Ltd. Bhopal, India ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 30: Product Pipeline
Product Pipeline RESEARCH DEVELOPMENT VALIDATION / TRIALS COMMERCIALIZATION qPCR Assays - Solid Tumours and Liquid Biopsy 2019 qPCR Assays - Infectious Panels 2019/20 NGS Assays – Solid Tumours 2020 ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 31: Our National Presence
Our National Presence TRUPCR® range of products are currently used by: 150+ customers Across 37 Cities ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 32: Our Global Presence
Our Global Presence And NOW !!! TRUPCR® is gaining its global footprints With High Sub-Continent presence with Neighbouring Countries And Also started business with customers across South East Asia & Middle East Products undergoing Validation in USA Final stage price negotiation in Latin America & S
Slide 33: New Customers added in Q4 2018-19
New Customers added in Q4 2018-19 Diagnostic Laboratory Nepal Diagnostic Laboratory Taiwan Diagnostic Laboratory in 2 Hospitals Bangladesh 2 Standalone Diagnostic Laboratory Hyderabad Standalone Diagnostic Laboratory Delhi Standalone Diagnostic Laboratory Kerala Cancer Hospital Assam Standalone Diag
Slide 34: New Products Launched in Q4 2018-19
New Products Launched in Q4 2018-19 • TRUPCR® Chikungunya/ Dengue & Zika virus Kit- Detection Kit Detection of Chikungunya/ Dengue & Zika virus on real-time PCR • TRUPCR® Rif/ INH MTB Drug Resistance Detection Kit – Detection of MTBC and resistance to Rifampicin & Isoniazid using real-time PCR • TRU
Slide 35: Target Customer Segments
Target Customer Segments Indian IVD/MDx Market Hospital Labs Stand-alone Pharma Labs Govt. Private Pathologist(s) Corporate CLINICAL Hospitals Hospitals Labs Labs TRIALS Secondary Central Govt. State Govt. Targeted Corporate Other Private National Regional National Labs Regional Labs Hospitals Hospi
Slide 36: TRUPCR Global Recognition
TRUPCR® Global Recognition Complete Includes Simultaneous Location of workflow Reverse Alignment step for Major Company Sensitivity Company solution Transcriptase with IS and Minor available step design transcript France, Europe Elitech - PCR alert kit MR4.0 ✗ ✗ WHO ✗ 3B BlackBio - TRUPCR® INDIA MR4
Slide 37: Contractual Business
Contractual Business • We are happy to inform that the Company to ensure long term assured business, has started signing long term (2-3 yr) contract with large customers. • As on date the company has five contracts running out of which 1 have been executed in this quarter which ensures yearly busine
Slide 38: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs External Growth • Evolution of disease profiles. New viruses and cancers are been diagnosed • Increase in evidence-based treatments / Drug re
Slide 39: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 40: Outstanding Achievement Award for Excellence in R&D
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‗Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category‘, during the 4th Outstanding Achievement Award 2016, held o
Slide 41: Thank You
Thank You ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH